Overview

Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension

Status:
Completed
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the safety and efficacy and Pharmacokinetics/Pharmacodynamics of SHR0532 in subjects with mild hypertension for 4 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Hydrochlorothiazide